High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT
- DOI
- 10.1182/bloodadvances.2026020219
- Published
- 2026-08-17
- Container
- Blood Advances
- Publisher
- American Society of Hematology
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1182/bloodadvances.2026020219,
title = {High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT},
author = {Joseph Kauer and Isabelle Krämer and Patrick Derigs and Maximilian Felix Blank and Sascha Dietrich and Julia Meissner and Niklas Kehl and Mirco Julian Friedrich and Maria-Luisa Schubert and Anthony Dick Ho and Anita Schmitt and Guido Kobbe and Carsten Müller-Tidow and Michael Schmitt and Peter Dreger},
year = {2026},
journal = {Blood Advances},
doi = {10.1182/bloodadvances.2026020219},
url = {https://doi.org/10.1182/bloodadvances.2026020219}
}RIS
TY - JOUR TI - High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT AU - Joseph Kauer AU - Isabelle Krämer AU - Patrick Derigs AU - Maximilian Felix Blank AU - Sascha Dietrich AU - Julia Meissner AU - Niklas Kehl AU - Mirco Julian Friedrich AU - Maria-Luisa Schubert AU - Anthony Dick Ho AU - Anita Schmitt AU - Guido Kobbe AU - Carsten Müller-Tidow AU - Michael Schmitt AU - Peter Dreger PY - 2026 JO - Blood Advances DO - 10.1182/bloodadvances.2026020219 UR - https://doi.org/10.1182/bloodadvances.2026020219 ER -
APA
Kauer, J., Krämer, I., Derigs, P., Blank, M. F., Dietrich, S., Meissner, J., Kehl, N., Friedrich, M. J., Schubert, M., Ho, A. D., Schmitt, A., Kobbe, G., Müller-Tidow, C., Schmitt, M., & Dreger, P. (2026). High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT. Blood Advances. https://doi.org/10.1182/bloodadvances.2026020219
Source records
- crossref · retrieved 2026-09-25T22:11:38.991Z